$JUBLPHARMA Share Price: Nuvama maintains 'BUY' rating despite montreal drag - Check target

Jubilant Pharmova Share Price: Shares of Jubilant Pharmova are likely to remain in focus after brokerage firm Nuvama Research reiterated its ‘BUY’ rating on the stock and set a 12-month share price target. Despite trimming near-term estimates due to challenges at the Montreal facility, the brokerage remains optimistic about the company’s long-term growth prospects, driven by strong momentum in its CDMO business. With the stock recently closing at Rs 1,006, the revised target suggests a potential upside of over 13 per cent from current levels.